Barclays
CYCN icon

Barclays’s Cyclerion Therapeutics CYCN Stock Holding History

Barclays’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5
Closed -$12 – 5327
2025
Q3 		$12 Buy
+5
New +$14 ﹤0.01% 5386
2021
Q4 		– Sell
-115
Closed -$7K – 4210
2021
Q3 		$7K Sell
115
-106
-48% -$6.94K ﹤0.01% 4564
2021
Q2 		$17K Sell
221
-705
-76% -$44.1K ﹤0.01% 4529
2021
Q1 		$52K Buy
926
+569
+159% +$42.7K ﹤0.01% 4188
2020
Q4 		$22K Sell
357
-152
-30% -$10.4K ﹤0.01% 4657
2020
Q3 		$62K Sell
509
-150
-23% -$17.2K ﹤0.01% 4491
2020
Q2 		$77K Buy
659
+268
+69% +$22.4K ﹤0.01% 4686
2020
Q1 		$20K Sell
391
-790
-67% -$56.4K ﹤0.01% 5641
2019
Q4 		$64K Buy
1,181
+591
+100% +$55.2K ﹤0.01% 5665
2019
Q3 		$143K Sell
590
-171
-22% -$36.9K ﹤0.01% 5199
2019
Q2 		$174K Buy
+761
New +$215K ﹤0.01% 5242

Other funds holding CYCN

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Barclays's CYCN Position: Q4 2025 in Review

Barclays sold out of Cyclerion Therapeutics (CYCN) in Q4 2025, closing a stake of 5 shares — an estimated $12 sold.

Barclays first reported a position in CYCN in Q2 2019 and held it in 11 quarters. The position peaked at $174K in Q2 2019. 19 funds tracked by Wall St. Rank hold CYCN as of Q4 2025.

  • Barclays reported no remaining Cyclerion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 5 Cyclerion Therapeutics shares in Q4 2025, an estimated $12.
  • Barclays first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 11 quarters.
  • Barclays's Cyclerion Therapeutics position peaked at $174K in Q2 2019.
  • 19 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.